Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older
Conditions
Interventions
Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)
High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
Locations
17
Belgium
Investigational Site Number 0560001
Ghent, Belgium
Investigational Site Number 0560002
Wilrijk, Belgium
Investigational Site Number 2500001
Gières, France
Investigational Site Number 2500004
Paris, France
Investigational Site Number 2500003
Pierre-Bénite, France
Investigational Site Number 2760003
Berlin, Germany
Start Date
October 28, 2019
Primary Completion Date
January 9, 2020
Completion Date
June 5, 2020
Last Updated
September 12, 2025
NCT07310264
NCT06342713
NCT07472361
NCT06823947
NCT06649110
NCT07240675
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions